GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » PS Ratio

RemeGen Co (HKSE:09995) PS Ratio : 22.16 (As of May. 14, 2024)


View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, RemeGen Co's share price is HK$30.25. RemeGen Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.37. Hence, RemeGen Co's PS Ratio for today is 22.16.

Good Sign:

RemeGen Co Ltd stock PS Ratio (=14.4) is close to 2-year low of 14.4

The historical rank and industry rank for RemeGen Co's PS Ratio or its related term are showing as below:

HKSE:09995' s PS Ratio Range Over the Past 10 Years
Min: 22.04   Med: 45.11   Max: 126.97
Current: 22.15

During the past 6 years, RemeGen Co's highest PS Ratio was 126.97. The lowest was 22.04. And the median was 45.11.

HKSE:09995's PS Ratio is ranked worse than
67.84% of 998 companies
in the Biotechnology industry
Industry Median: 9.14 vs HKSE:09995: 22.15

RemeGen Co's Revenue per Sharefor the three months ended in Dec. 2023 was HK$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.37.

During the past 12 months, the average Revenue per Share Growth Rate of RemeGen Co was 35.10% per year.

During the past 6 years, RemeGen Co's highest 3-Year average Revenue per Share Growth Rate was 409.80% per year. The lowest was 409.80% per year. And the median was 409.80% per year.

Back to Basics: PS Ratio


RemeGen Co PS Ratio Historical Data

The historical data trend for RemeGen Co's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co PS Ratio Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial - - 21.74 35.87 17.18

RemeGen Co Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.87 39.23 36.21 17.18 -

Competitive Comparison of RemeGen Co's PS Ratio

For the Biotechnology subindustry, RemeGen Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RemeGen Co's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's PS Ratio distribution charts can be found below:

* The bar in red indicates where RemeGen Co's PS Ratio falls into.



RemeGen Co PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

RemeGen Co's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=30.25/1.365
=22.16

RemeGen Co's Share Price of today is HK$30.25.
RemeGen Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$1.37.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


RemeGen Co  (HKSE:09995) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


RemeGen Co PS Ratio Related Terms

Thank you for viewing the detailed overview of RemeGen Co's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


RemeGen Co (HKSE:09995) Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

RemeGen Co (HKSE:09995) Headlines

No Headlines